Pasar al contenido principal


Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Conexión rápida

Anti-Diabetic API Products

Get access to Dr. Reddys largest Anti-diabetic API portfolios to support your formulation success.

Dr. Reddy's offers a wide selection of anti-diabetic active pharmaceutical ingredients used in the production of formulations to treat a wide range of metabolic diseases. Catering to the needs of anti-diabetic formulators, we have been manufacturing and supplying anti-diabetic APIs for over two decades.

Meeting the needs of formulation manufacturers, Dr. Reddy's provides customized particle size distribution for Anti-diabetic APIs. We are a reliable API partner with a de-risked supply chain model and complete backward integration, ensuring timely supplies to meet your demand.

Dr. Reddy's has been recognized as one of the largest, reliable manufacturers of Anti-diabetic APIs. With a production capability of multi-tonnes per year, our APIs are part of medicines across the globe, formulated by partners around the world.

We offer a broad portfolio of APIs catering to Anti- Diabetic therapy, understanding the global demand, and supporting our customers with their launch requirements. Some of the critical classes of APIs under our Anti-diabetic portfolio include:

Our team of process and analytical experts draw on their integrated understanding of IP, regulatory affairs, process development (API & formulation), and API manufacturing to ensure early entry into the market. This is of particular importance to select the optimal synthesis route in the context of the IP situation.

Other aspects are the solid-state forms and particle characteristics that are critical in formulation development. Therefore, extensive analytical tools and techniques such as 1H NMR, 13 C NMR, 2 D NMR, HRMS, DSC, TGA, IR, SEM, and PXRD have been used to elucidate the API structure, compare the different solid forms, and demonstrate the chemical and physical attributes of the API.

It is ensured that the APIs are free from potential genotoxic and carcinogenic impurities, and a control strategy has been defined by using the QbD approach at every step of the synthesis.

We stay committed to ensuring that we continue to provide high-quality and safe APIs to our partners

We offer:

  • End to end solutions
  • Best in class quality
  • cGMP manufacturing capacities
  • Continuous process innovation
  • Back-ward integration
  • Consistent supply on a commercial scale.
  • Regulatory and early launch advantage
Explore Anti-Diabetic Products

Canagliflozin Hemihydrate

Categoría terapéutica
Anti-diabético

Clorhidrato De Sitagliptina

Categoría terapéutica
Anti-diabético

Dapagliflozina (amorfa)

Categoría terapéutica
Anti-diabético

Doxazosin Mesylate

Categoría terapéutica
Anti-diabético

Fosfato De Sitagliptina

Categoría terapéutica
Anti-diabético

Glimepirida

Categoría terapéutica
Anti-diabético

Linagliptina

Categoría terapéutica
Anti-diabético

Liraglutida

Categoría terapéutica
Anti-diabético

Pioglitazona Clorhidrato

Categoría terapéutica
Anti-diabético

Repaglinide

Categoría terapéutica
Anti-diabético

Semaglutida

Categoría terapéutica
Anti-diabético

Tirzepatide

Categoría terapéutica
Anti-diabético

 

Dr. Reddy’s is well-positioned to meet the global demand for Anti-Diabetic APIs. As for many of our APIs, the key starting materials (KSM) are backward integrated today. We’ve also established strategic solid sourcing and logistics partnerships and work closely with our customers to successfully manage the capacities of our manufacturing units ahead of launches.

To know more about our end-to-end solutions for Anti-diabetic formulations and Dosage forms. Check out our board portfolio of Anti-Diabetic APIs here (or) Contact us at api@drreddys.com.

Explore other Therapeutic categories.

FAQs

The major Anti-diabetic APIs are classified as:

  • Sodium-glucose co-transporter 2 (SGLT2) inhibitors
  • Glucagon-like peptide-1
  • Sulfonylureas
  • Thiazolidinediones

Antidiabetic APIs act by:

  • Direct stimulation of the GLP-1
  • Increase insulin secretion from pancreatic β-cells
  • Reduce glucagon release
  • Gluconeogenesis and causes a decrease in insulin resistance
  • Reduce intestinal glucose absorption
  • Increased glucosuria through the inhibition of SGLT-2 in the kidney

The Antidiabetics Market size was USD 85.5 billion in 2022 and will grow at a CAGR of 10.7% from 2022 to 2026.

In May 2022, the FDA approved Mounjaro (also known as tirzepatide) for type 2 diabetes management and diet and exercise. This first-in-class medication has been shown to improve glucose levels and weight dramatically in clinical trials.

Renuncia

Ninguna información en este catálogo, incluida cualquier referencia a cualquier producto o servicio, constituye una oferta de venta, ni debe interpretarse como representación de una oferta de venta. Los productos protegidos por patentes válidas no se ofrecen ni se suministran para uso comercial. Sin embargo, las cantidades de investigación de dichos productos pueden ofrecerse con el fin de presentaciones reglamentarias, siempre que existan dichas exenciones reglamentarias. Los compradores deben realizar una evaluación independiente del escenario de la patente para sus respectivos mercados y serán responsables de todas las responsabilidades relacionadas con la patente. Los productos protegidos por patentes válidas en la India no están disponibles para uso comercial, pero estarían disponibles para los fines de la Sección 107A.

X
Checked out our

API Linkedin
page yet?

Follow this page to explore how our offerings can accelerate your formulation success

Click here to visit